Excretion of infectious hepatitis E virus into milk in cows imposes high risks of zoonosis

Fen Huang, Yunlong Li, Wenhai Yu, Shenrong Jing, Jue Wang, Feiyan Long, Zhanlong He, Chenchen Yang, Yanhong Bi, Wentao Cao, Chengbo Liu, Xiuguo Hua, Qiuwei Pan – 10 June 2016 – Hepatitis E virus (HEV) represents the main cause of acute hepatitis worldwide. HEV infection in immunocompromised patients involves a high risk for the development of chronic hepatitis. Because HEV is recognized as a zoonotic pathogen, it is currently believed that swine is the primary reservoir.

Reply

Eduardo Vilar‐Gomez, Luis Calzadilla‐Bertot, Scott L. Friedman, Manuel Romero‐Gomez – 10 June 2016

LiverLearning®: 2016 Webinar: Fibrates in the Context of Cholestatic Diseases

Webinar hosted by the Cholestatic and Biliary Diseases Special Interest group on June 9, 2016.Olivier Barbier (Moderator) Carlo Spirli (Moderator) Cynthia Levy Cynthia Levy, MD, FAASLD is a Professor of Medicine in the Division of Digestive Health and Liver Diseases and is the Associate Director of the Schiff Center for Liver Diseases at the University of Miami. She was awarded the Arthur Hertz Endowed Chair in Liver Diseases. Dr. Levy received her M.D. from Universidade Federal do Rio de Janeiro (UFRJ).

Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen–positive liver transplant recipients after longterm minimal immunosuppression

Ilaria Lenci, Leonardo Baiocchi, Laura Tariciotti, Daniele Di Paolo, Martina Milana, Francesco Santopaolo, Tommaso Maria Manzia, Luca Toti, Valentina Svicher, Giuseppe Tisone, Carlo Federico Perno, Mario Angelico – 7 June 2016 – Tailored approaches have been attempted to prevent hepatitis B virus (HBV) reinfection in antibodies against hepatitis B surface antigen (HBsAg)–positive liver transplantation (LT) recipients in order to minimize the use of hepatitis B immune globulin (HBIG) and nucleoside analogues (NAs).

A highly specific and sensitive hepatitis C virus antigen enzyme immunoassay for One‐step diagnosis of viremic hepatitis C virus infection

Ke‐Qin Hu, Wei Cui – 6 June 2016 – The current standard in diagnosing hepatitis C virus (HCV) infection requires two sequential steps: anti‐HCV test to screen, followed by HCV RNA reverse‐transcription polymerase chain reaction to confirm viremic HCV (V‐HCV) infection. HCV core antigen tests provided potential for possible one‐step diagnosis. However, low sensitivity and specificity limit their clinical utility.

Subscribe to